Celldex Therapeutics Inc
CLDXHealthcare|Biotechnology|USA
$39.11
+0.14 (+0.36%)
Tangible Book
$6.45
Clinical Trials (73)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06445023 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | P3 | Active | 963 | RCT, Double-blind | barzolvolimab, Matching placebo |
| NCT06455202 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Spontaneous Urticaria | P3 | Active | 976 | RCT, Double-blind | barzolvolimab, Matching placebo |
| NCT07266402 A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) | Chronic Inducible Urticaria, Cold Urticaria | P3 | Recruiting | 240 | RCT, Double-blind | Barzolvolimab, Matching Placebo |
| NCT05231122 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | P2 | Recruiting | 80 | RCT, Single-blind | Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab |
| NCT06366750 A Study of Barzolvolimab in Patients With Prurigo Nodularis | Prurigo Nodularis | P2 | Active | 140 | RCT, Double-blind | barzolvolimab |
| NCT06727552 A Study of Barzolvolimab in Patients With Atopic Dermatitis | Atopic Dermatitis | P2 | Active | 131 | RCT, Double-blind | Barzolvolimab, Matching placebo |
| NCT03804944 Converting HR+ Breast Cancer Into an Individualized Vaccine | Breast Cancer | P2 | Recruiting | 100 | RCT, Open-label | Pembrolizumab (200mg IV for 30 minutes, CDX-301 |
| NCT03688178 DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | Glioblastoma | P2 | Active | 43 | RCT, Double-blind | Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td, Unpulsed DCs |
| NCT05029999 CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | HER2-negative Breast Cancer, Metastatic Breast Cancer | P1 | Recruiting | 30 | RCT, Open-label | PLD Chemotherapy, CDX-1140, CDX-301 |
| NCT07330778 A Study of CDX-622 in Participants With Mild to Moderate Asthma | Mild to Moderate Asthma | P1 | Recruiting | 12 | Open-label | CDX-622 |
| NCT04930783 NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | Melanoma, Metastatic Melanoma | P1 | Active | 10 | Open-label | CDX-301, NEOVAX, Nivolumab, Pembrolizumab |
| NCT05349890 Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | Malignant Epithelial Neoplasms | P1 | Active | 1 | Open-label | TCR-transduced T cells, CDX-1140, Pembrolizumab |
| NCT07256392 Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | P3 | By Invite | 1,370 | Open-label | barzolvolimab |
| NCT01480479 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | Glioblastoma, Small Cell Glioblastoma | P3 | Completed | 745 | RCT, Double-blind | Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH |
| NCT05368285 A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | P2 | Completed | 208 | RCT, Double-blind | barzolvolimab, Matching Placebo |
| NCT03617328 Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | Melanoma | P1P2 | Completed | 33 | RCT, Open-label | 6MHP, Montanide ISA-51, polyICLC, CDX-1127 |
| NCT00412828 A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | Unresectable Stage III or Stage IV Melanoma | P1P2 | Completed | 117 | Open-label | CR011-vcMMAE |
| NCT01156753 A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | Breast Cancer | P2 | Completed | 120 | RCT, Open-label | CDX-011, "Investigator's Choice" chemotherapy |
| NCT00948961 A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | Advanced Malignancies | P1P2 | Completed | 70 | Open-label | CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod, poly-ICLC |
| NCT03580382 Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | Melanoma | P1P2 | Terminated | 3 | Open-label | Trametinib daily Until PD, CDX-3379 (ERBB3 antibody) |
| NCT03254927 A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | P2 | Terminated | 30 | Open-label | CDX-3379 and cetuximab |
| NCT02200380 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | P2 | Terminated | 36 | Open-label | CDX-301, CDX-301 and plerixafor |
| NCT02713828 Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung | Squamous Cell Carcinoma of the Lung | P1P2 | Terminated | 13 | Open-label | Phase I: Glembatumumab Vedotin, Phase II: Glembatumumab Vedotin |
| NCT02166905 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Fallopian Tube Carcinoma, Ovarian Carcinoma | P1P2 | Completed | 40 | RCT, Open-label | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Poly ICLC |
| NCT00104065 Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant | Stomatitis | P2 | Completed | — | RCT, Double-blind | CG53135-05, velafermin |
| NCT02335918 A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed | P1P2 | Completed | 175 | Open-label | Combination of varlilumab and nivolumab |
| NCT00458601 Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | Malignant Glioma | P2 | Completed | 82 | Open-label | CDX-110 with GM-CSF, Temozolomide |
| NCT01094496 A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | Bladder Cancer | P2 | Terminated | 3 | Open-label | CDX-1307 Vaccine Regimen, Chemotherapy |
| NCT01997333 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | P2 | Completed | 327 | RCT, Open-label | CDX-011, Capecitabine |
| NCT02302339 A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | Melanoma | P2 | Terminated | 132 | Open-label | glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), glembatumumab vedotin and CDX-301 |
| NCT05405660 A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | Chronic Inducible Urticaria | P2 | Completed | 196 | RCT, Double-blind | barzolvolimab, Matching Placebo |
| NCT05774184 A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | P2 | Completed | 86 | RCT, Double-blind | barzolvolimab, Matching Placebo |
| NCT03307746 A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma | B Cell Lymphoma | P1P2 | Completed | 26 | RCT, Open-label | Varlilumab |
| NCT01976585 In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Low-Grade B-cell Lymphoma | P1P2 | Completed | 21 | Open-label | rhuFlt3L/CDX-301, Poly-ICLC |
| NCT00704158 Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer | Breast Cancer | P1P2 | Completed | 42 | Open-label | CR011-vcMMAE |
| NCT02413827 A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | Unresectable Stage III or Stage IV Melanoma | P1P2 | Terminated | 9 | Open-label | Combination of varlilumab and ipilimumab, Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC |
| NCT04536077 Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Pancreatic Cancer, Cancer of the Pancreas | P2 | Terminated | 16 | RCT, Open-label | CDX-301, CDX-1140 |
| NCT01498328 A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | Glioblastoma, Small Cell Glioblastoma | P2 | Completed | 127 | RCT, Double-blind | Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH |
| NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC | Non-Hodgkin's Lymphoma, Metastatic Breast Cancer | P1P2 | Completed | 17 | Open-label | Pembrolizumab, Flt3L, Poly ICLC |
| NCT04491084 FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy | Non Small Cell Lung Cancer, Lung Cancer | P1P2 | Terminated | 5 | RCT, Open-label | FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140) |
| NCT04364230 Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | Melanoma, Ocular Melanoma | P1P2 | Completed | 22 | Open-label | 6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140 |
| NCT02839265 FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer | Non-small Cell Lung Cancer (NSCLC) | P2 | Completed | 33 | Open-label | FLT3 Ligand Therapy (CDX-301) |
| NCT00323518 A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis | Oral Mucositis, Stomatitis | P2 | Completed | 390 | RCT, Double-blind | velafermin, placebo |
| NCT02543645 A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Carcinoma, Renal Cell, Kidney Diseases | P1 | Terminated | 18 | Open-label | Combination of Varlilumab and Atezolizumab |
| NCT02270372 Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | Advanced Breast Carcinoma, Advanced Ovarian Carcinoma | P1 | Completed | 22 | Open-label | ONT-10, Varlilumab combination |
| NCT03835533 Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations | Metastatic Castration-resistant Prostate Cancer | P1 | Completed | 43 | Open-label | NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C) |
| NCT05484011 A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | P1 | Terminated | 5 | Open-label | odetiglucan, CDX-1140 |
| NCT04944862 A Study of CDX-0159 in Patients With Prurigo Nodularis | Prurigo Nodularis | P1 | Completed | 24 | RCT, Double-blind | CDX-0159, Normal saline |
| NCT05788484 A Study of CDX-585 in Patients With Advanced Malignancies | Non-small Cell Lung Cancer, Gastric Cancer | P1 | Completed | 20 | Open-label | CDX-585 |
| NCT01460134 A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | P1 | Completed | 90 | Open-label | CDX-1127, CDX-1127, CDX-1127 |
| NCT04548869 A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | Cold Urticaria, Cold Contact Urticaria | P1 | Completed | 41 | Open-label | CDX-0159 |
| NCT02473731 A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Squamous Cell Carcinoma of the Head and Neck | P1 | Completed | 12 | RCT, Open-label | KTN3379 |
| NCT01791686 Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II | P1 | Terminated | 1 | Open-label | CDX-1135 |
| NCT02456701 Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | Thyroid Cancer | P1 | Completed | 7 | Open-label | KTN3379, vemurafenib |
| NCT02014909 A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Advanced Cancer | P1 | Completed | 64 | Open-label | KTN3379 |
| NCT06650761 A Phase I Study of CDX-622 | Healthy Participants | P1 | Completed | 85 | RCT, Double-blind | CDX-622, Normal Saline |
| NCT02924038 A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | Glioma, Malignant Glioma | P1 | Terminated | 14 | RCT, Open-label | IMA950, poly-ICLC, Varlilumab |
| NCT00648102 Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | Breast Cancer, Colorectal Cancer | P1 | Completed | 36 | Open-label | CDX-1307 |
| NCT04146129 A Phase 1 Study of CDX-0159 | Healthy Subjects | P1 | Completed | 32 | RCT, Double-blind | CDX-0159, Normal saline |
| NCT02642016 A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors | Advanced Cancer | P1 | Completed | 28 | Open-label | CDX-0158 (formerly known as KTN-0158) |
| NCT03329950 A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | Melanoma, Non-small Cell Lung Cancer | P1 | Completed | 132 | Open-label | CDX-1140, CDX-301, pembrolizumab, Chemotherapy |
| NCT05031624 A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | Healthy Subjects | P1 | Completed | 32 | RCT, Double-blind | CDX-0159, Normal saline |
| NCT00709462 A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | Breast Cancer, Colorectal Cancer | P1 | Completed | 48 | Open-label | CDX1307 |
| NCT03358719 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells | P1 | Completed | 8 | Open-label | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Nivolumab, Poly ICLC |
| NCT02386111 A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | Carcinoma, Renal Cell, Kidney Diseases | P1 | Terminated | 17 | Open-label | Combination of varlilumab and sunitinib |
| NCT01465139 A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers | Healthy | P1 | Completed | 30 | Open-label | CDX-301 |
| NCT04440943 A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | Non-small Cell Lung Cancer, Breast Cancer | P1 | Completed | 27 | Open-label | CDX-527 |
| NCT04538794 A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | P1 | Completed | 45 | RCT, Double-blind | CDX-0159, Normal Saline |
| NCT02837991 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma | P1 | Terminated | 16 | Open-label | CDX-014 |
| NCT02284971 Pilot Study of SBRT and CDX-1127 in Prostate Cancer | Prostatic Neoplasms, Prostate Cancer | P1 | Terminated | 2 | RCT, Open-label | CDX1127 |
| NCT03067935 Individual Patient Expanded Access-Glembatumumab Vedotin | Metastatic gpNMB Expressing Triple Negative Breast Cancer | NO_LONGER_AVAILABLE | — | — | glembatumumab vedotin | |
| NCT03068650 Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut | Recurrent GBM | NO_LONGER_AVAILABLE | — | — | rindopepimut | |
| NCT03473691 Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer | Triple Negative Breast Cancer | Early P1 | Withdrawn | — | Open-label | Glembatumumab Vedotin |